ARTICLE | Company News
Caladrius Biosciences, AiVita Biomedical deal
June 6, 2016 7:00 AM UTC
Caladrius granted AiVita exclusive, worldwide rights to tumor cell/dendritic cell technology to treat ovarian cancer. Caladrius is eligible for undisclosed development milestones and royalties. AiVita...